Efficacy and safety of first-line therapy with fulvestrant or exemestane for postmenopausal ER+/HER2-advanced breast cancer patients after adjuvant nonsteroidal aromatase inhibitor treatment: A randomized, open-label, multicenter study
机构：[1]Medical Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, China[2]Medical Oncology, Affiliated Tumor Hospital of Harbin Medical University, Harbin, China[3]Medical Oncology, The First Affiliated Hospital of Jilin University, Changchun, China[4]Oncology, Liaoning Province Cancer Hospital, Shenyang, Liaoning, China[5]Medical Oncology, The First Affiliated Hospital of China Medical University, Chenyang, China[6]Medical Oncology, Tianjin Cancer Hospital, Tianjin, China[7]Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China[8]Department of Breast Cancer Internal Medicine, Hunan Cancer Hospital, Changsha, China[9]Oncology, Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[10]Breast Cancer Center, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China河南省肿瘤医院[11]Medical Oncology, Traditional Chinese Medicine Hospital of Guangdong Province, Guangzhou, China广东省中医院[12]Oncology Department, Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, Nanjing, China江苏省人民医院[13]Surgical Oncology, Peking Union Medical College Hospital, Beijing, China[14]Surgical Oncology, Guangdong Provincial People’s Hospital, Guangzhou, China[15]Medical Oncology Department, Jiangsu Cancer Hospital, Nanjing, China[16]Department of Breast Cancer Internal Medicine, Cancer Hospital of The University of Chinese Academy of Sciences, Hangzhou, China浙江省肿瘤医院
第一作者机构：[1]Medical Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, China
推荐引用方式(GB/T 7714)：
J.Wang,B. Xu,L. Cai,et al.Efficacy and safety of first-line therapy with fulvestrant or exemestane for postmenopausal ER+/HER2-advanced breast cancer patients after adjuvant nonsteroidal aromatase inhibitor treatment: A randomized, open-label, multicenter study[J].ANNALS OF ONCOLOGY.2021,32:S461-S462.doi:10.1016/j.annonc.2021.08.518.
APA：
J.Wang,B. Xu,L. Cai,Y. Song,L. Kang...&X. Wang.(2021).Efficacy and safety of first-line therapy with fulvestrant or exemestane for postmenopausal ER+/HER2-advanced breast cancer patients after adjuvant nonsteroidal aromatase inhibitor treatment: A randomized, open-label, multicenter study.ANNALS OF ONCOLOGY,32,
MLA：
J.Wang,et al."Efficacy and safety of first-line therapy with fulvestrant or exemestane for postmenopausal ER+/HER2-advanced breast cancer patients after adjuvant nonsteroidal aromatase inhibitor treatment: A randomized, open-label, multicenter study".ANNALS OF ONCOLOGY 32.(2021):S461-S462
医学